Skip to main content

Table 1 Demographics and clinical information

From: Relationship of cell-free urine MicroRNA with lupus nephritis in children

Features

n of N (%)

Mean (SD)

Lupus patients Controls

Lupus Nephritis (LN),n, age (years)

14 18.33 ± 3.77

SLE without LN,n, age (years)

10 17.40 ± 2.59

Fibromyalgia

5

Juvenile Idiopathic Arthritis

5

Females

 

19 (79.1 %)

Race

Black

13 (54.1 %)

 

White

8 (33.4 %)

 

Other°

3 (12.5 %)

Medications (SLE patients)

Oral prednisone (mg/day)

24 (100 %)

26.1 (18.4)

Mycophenolate mofetil

10 (41.7 %)

Azathioprine

1 (4.1 %)

Cyclophosphamide

10 (41.7 %)

Diuretics

4 (16.6 %)

Angiotensin system blocking drug

12 (50 %)

LN Status (n = 14)

GFR£ < 60 ml/min/m2

3 (21.4 %)

 

Protein:creatinine ratio > 0.5

11 (78.6 %)

 

Renal SLEDAI* score

 

5.6 (6.19)

Renal BILAG score

 

4.8 (4.54)

      Class 2

4 (28.6 %)

 

ISN/RPS  Class 3

2 (14.3 %)

      Class 4

7 (50 %)

      Class 5

1 (7.1 %)

SLE Status (n = 24)

Complement C3 low

9 (37.5 %)

 

Complement C4 low

16 (66.7 %)

Presence of anti-dsDNA antibodies

18 (75 %)

  1. *Systemic Lupus Erythematosus Disease Activity Index, range 0–105; 0 – inactive LN
  2. ¶International Society for Nephrology Renal Pathology Society Class; there was no biopsy consistent with Class I or VI; °Other: includes Asians, Mixed race, Native Indian
  3. £GFR as estimated by the modified Schwartz formula